Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Operating Leases (2019 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Operating Leases for 4 consecutive years, with $44.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases changed 0.08% to $44.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $44.4 million, a 0.08% change, with the full-year FY2025 number at $44.4 million, changed 0.08% from a year prior.
  • Operating Leases was $44.4 million for Q4 2025 at Iovance Biotherapeutics, down from $45.2 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $72.3 million in Q1 2024 to a low of $44.2 million in Q1 2025.
  • A 3-year average of $56.9 million and a median of $56.1 million in 2023 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: rose 3.85% in 2024, then crashed 38.83% in 2025.
  • Iovance Biotherapeutics' Operating Leases stood at $67.1 million in 2023, then tumbled by 33.87% to $44.4 million in 2024, then rose by 0.08% to $44.4 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Operating Leases are $44.4 million (Q4 2025), $45.2 million (Q3 2025), and $45.1 million (Q2 2025).